Cancer biosimilars associated with lower costs for insurers and patients

Biologic drugs play an important relation successful treating cancers specified arsenic bosom crab and lymphoma, but their precocious costs tin adhd to the fiscal load of crab care. Now, lower-cost versions known arsenic biosimilars are gaining ground, and a caller survey led by researchers astatine the UCLA Health Jonsson Comprehensive Cancer Center suggests their increasing usage is associated with little costs for some insurers and patients.